Mogrify

Mogrify Limited is a UK-based regenerative medicine company that focuses on developing innovative cellular reprogramming technologies. Founded in February 2016, Mogrify aims to create *in vivo* reprogramming therapies for degenerative diseases, particularly in fields such as otology, ophthalmology, and diabetes. The company is dedicated to transforming patient lives by recovering lost cell types and restoring organ function directly in the body. Mogrify utilizes a proprietary platform that combines big-data analysis, transcriptomic and epigenetic sequencing, and advanced computational modeling. This technology allows for systematic cell conversion without intermediate pluripotent states, supporting a pipeline of therapies aimed at addressing degenerative conditions. The company is actively engaged in internal therapy development, co-development partnerships, and exploring various applications of its platform in both therapeutic and non-therapeutic areas. With total funding exceeding £37 million, Mogrify is well-positioned to make significant contributions to the regenerative medicine market.